Search Results for 'Nivolumab-Cont'

Nivolumab-Cont published presentations and documents on DocSlides.

Phase II studies of Nivolumab

Phase II studies of Nivolumab

by brianna

in patients with Advanced . Squamous. (SQ) or Non...

Nivolumab + Ipilimumab

Nivolumab + Ipilimumab

by willow

vs . Platinum-Doublet Chemotherapy . as First-line...

Please refer to CCMB Formulary for Criteria for Use

Please refer to CCMB Formulary for Criteria for Use

by joanne

ADULTUpdated November 122019Page 1of 2Regimen Refe...

Please refer to CCMB Formulary for Crit

Please refer to CCMB Formulary for Crit

by patricia

ADULT Updated: October 2 8 , 20 20 eria for Use Pa...

NA_00092076/ J1414, Protocol Version 4.8 Dated 13November2018

NA_00092076/ J1414, Protocol Version 4.8 Dated 13November2018

by singh

1 Study Title: Neoadjuvant Nivolumab, or Nivoluma...

Please note, these are the

Please note, these are the

by vizettan

actual. . video-recorded proceedings from the . l...

Please note, these are the actual video-recorded

Please note, these are the actual video-recorded

by min-jolicoeur

proceedings from the live CME event and may inclu...

Expanding Treatment Options in SCCHN: What Role Do Cancer Immunotherapies Have?

Expanding Treatment Options in SCCHN: What Role Do Cancer Immunotherapies Have?

by marina-yarberry

Expanding Treatment Options in SCCHN: What Role D...

James L. Gulley M.D. , Ph.D.,

James L. Gulley M.D. , Ph.D.,

by tatyana-admore

F.A.C.P. .. Head, Immunotherapy Section. Chief, G...

Italian cohort of

Italian cohort of

by test

nivolumab. Expanded Access . Programme. (EAP): ...

Integration of Immunotherapy Across

Integration of Immunotherapy Across

by pamella-moone

the Spectrum of Lung Cancer. Karen Kelly, MD. Pro...

Integration of Immunotherapy Across

Integration of Immunotherapy Across

by karlyn-bohler

the Spectrum of Lung Cancer. Karen Kelly, MD. Pro...

Perioperative SACT in lUNg

Perioperative SACT in lUNg

by van

cancer. Dr Adam Dangoor. University Hospitals Bris...

Incorporating Immunotherapy in management of HNSCC

Incorporating Immunotherapy in management of HNSCC

by candy

ندوة أورام الرأس . و. العنق. ...

Checkpoint inhibitors for

Checkpoint inhibitors for

by paisley

NSCLC. An update. Solange Peters, MD-PhD. Oncology...

GI CONNECT MEETING SUMMARY

GI CONNECT MEETING SUMMARY

by hanah

upper . gi. cancer HIGHLIGHTS . FROM ESMO 2022. D...

YIR On Demand Lung Benjamin Levy, MD

YIR On Demand Lung Benjamin Levy, MD

by jovita

Assistant Professor. Johns Hopkins School of Medic...

Immuno-Oncology Applications

Immuno-Oncology Applications

by joy

Lee S. Schwartzberg,. MD, FACP. West Clinic, P.C....

Liver tumours Best of ILC 2019

Liver tumours Best of ILC 2019

by mackenzie

About these slides. These slides provide highlight...

EDDOP Program Update with EDDOP Accrual P30 Supplement Awardees

EDDOP Program Update with EDDOP Accrual P30 Supplement Awardees

by delcy

Jeff Moscow, M.D. Investigational Drug Branch, CTE...

by carla

ipilimumab/-UV1 vaccination as 2ndline treatment i...

Please note, these are the

Please note, these are the

by robaut

actual. . video-recorded proceedings from the . l...

Nouveautés dans le CBNPC métastatique

Nouveautés dans le CBNPC métastatique

by vizettan

Celine Mascaux, MD, . PhD. Multidisciplinary . Onc...

Immuno-Oncology Dr. Michael Palumbo

Immuno-Oncology Dr. Michael Palumbo

by mofferro

April 18, 2018. Immuno-Oncology. Activating the im...

Biomarkers for Cancer Immunotherapy: Understanding Their Growing Role in

Biomarkers for Cancer Immunotherapy: Understanding Their Growing Role in

by yoshiko-marsland

Pan Tumors. This program will include a discussio...

Raising the Bar in the Management of Advanced/Metastatic NSCLC

Raising the Bar in the Management of Advanced/Metastatic NSCLC

by debby-jeon

Dr Tan . Jiunn. Liang. Clinical Specialist (Resp...

Case Discussion A 52-year-old man initially presented with

Case Discussion A 52-year-old man initially presented with

by lois-ondreau

nonmuscle. -invasive . bladder cancer. He receive...

Overall survival and safety experience from an expanded access program (EAP) of nivolumab (NIVO) fo

Overall survival and safety experience from an expanded access program (EAP) of nivolumab (NIVO) fo

by olivia-moreira

Milton Barros e Silva,. 1. Rafael Schmerling,. 2...

Precision Medicine

Precision Medicine

by trish-goza

From Promise to Practice. PRECISION ONCOLOGY IS T...

Symptom Management of Novel Agents

Symptom Management of Novel Agents

by yoshiko-marsland

Amanda Dean, MSN, ACNP-BC, RNFA. Director of Adva...

by alida-meadow

Gandara. , MD. University of California, Davis . ...